Advicenne S.A. (FRA:3MM)

Market Cap	19.12M -7.5%
Revenue (ttm)	6.40M +21.6%
Net Income	-9.53M
EPS	-0.65
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.8670
Previous Close	0.8620
Day's Range	0.8430 - 0.8670
52-Week Range	0.8080 - 2.2000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 11
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3MM

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.